TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00602030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat tablets on Days 1 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat tablets on Days 1 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat tablets on Days 1 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat tablets on Days 1 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg tablets once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg tablets once daily.
Study: NCT02678195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Study: NCT03019965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Piperacillin/tazobactam
Description: Piperacillin/tazobactam administered in 30 minutes infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Piperacillin/tazobactam
Description: Piperacillin/tazobactam administered in 24 hours infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Imipenem
Description: Imipenem administered in 60 minutes infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Imipenem
Description: Imipenem administered in 6 hours infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Meropenem
Description: Meropenem administered in 60 minutes infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Meropenem
Description: Meropenem administered in 8 hours infusion.
Study: NCT04154709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTA101
Description: Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
Study: NCT00692653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P4
Description: Tailored online decision support system for prostate cancer treatment decision making
Study: NCT02879721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
Study: NCT01609764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One year fitness training
Description: Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
Study: NCT01241461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702
Description: Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met.
Study: NCT00719290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)
Description: Phacoemulsification of the lens with intraocular lens implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)
Description: Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
Study: NCT02763722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient spray product
Description: All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
Study: NCT06123507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Student practitioner perspective-taking intervention
Description: This intervention compares the outcomes where some learn about and practice perspective-taking and others do not. All participants received at least a partial intervention through getting video-feedback on their dialogue with a client actor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Student practitioner perspective-taking intervention
Description: This intervention compares the outcomes where some learn about and practice perspective-taking and others do not. All participants received at least a partial intervention through getting video-feedback on their dialogue with a client actor.
Study: NCT02082171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain intervention
Description: Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
Study: NCT03017196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Life, My Healthcare Discussion Aid
Description: The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
Study: NCT03320174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: Tafenoquine 200mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02145208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIND System
Description: An implant
Study: NCT01091870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate, 25 mg, 3 times a day.
Description: Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate 50 mg, 3 times a day
Description: Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
Study: NCT03034837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resin sealant
Description: Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART sealant
Description: Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once.
Study: NCT01096381

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood collection

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood collection

Intervention type: OTHER
Intervention: questionnaire administration
Description: Survey regarding baseline health and activity level.

Intervention type: OTHER
Intervention: questionnaire administration
Description: Survey regarding baseline health and activity level.
Study: NCT01918657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: walnut powder
Description: Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: walnut powder
Description: escalating doses of walnut powder
Study: NCT03902470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural anaesthesia video assisted thoracoscopic surgery
Description: Patients in (TEA) group will pre-medicated using midazolam 3-4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3-T4 and T4-T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anaesthesia video assisted thoracoscopic surgery
Description: Patients in (TEA) group will pre-medicated using midazolam 3-4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3-T4 and T4-T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.
Study: NCT03283930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Attention Bias Modification Training
Description: Computer-based attention bias modification training administered at weekly CBT session aimed at re-training attentional biases

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Bias Modification Training
Study: NCT01341093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational program+telephone follow up
Description: Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
Study: NCT00929344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized behavioral therapy
Description: Standardized behavioral therapy 1 time per week for 12 week duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized behavioral therapy
Description: Standardized behavioral therapy 1 time per week for 12 week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized behavioral therapy
Description: Standardized behavioral therapy 1 time per week for 12 week duration.
Study: NCT03298997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligation and Hemorrhoidopexy
Description: Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to pudendal nerve block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Ligation of Hemorrhoidal Arteries
Description: Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to spinal anesthesia.
Study: NCT03068689

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is \> 185mm HG the cuffs are inflated to 15 mmHG above that level.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01242241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
Study: NCT04338477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nephrosolid tablets
Description: Adminstration of drug
Study: NCT01853293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kudzu extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management
Description: Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
Study: NCT00109746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chromium picolinate
Description: HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
Study: NCT02260206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
Study: NCT02600611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iclaprim
Description: Experimental treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: Active comparator
Study: NCT04173416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Opioid Recovery Support (YORS)
Description: The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
Study: NCT00384202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppression
Study: NCT03134729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine for Serratus Plane Block (SPB)
Description: Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
Study: NCT02954549

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: As in Arms

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: As in Arms

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: As in Arms
Study: NCT02155985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for aspirin
Study: NCT02998151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: two 666mg pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: two 20mg pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: two 135mg pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: one 30mg pill
Study: NCT00870467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double-blind adalimumab
Description: Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double-blind adalimumab
Description: Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double-blind adalimumab
Description: Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-blind Placebo
Description: Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-blind Placebo
Description: Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-blind Placebo
Description: Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-label Adalimumab
Description: Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-label Adalimumab
Description: Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-label Adalimumab
Description: Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-label Adalimumab
Description: Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-labelAdalimumabRescue
Description: Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-labelAdalimumabRescue
Description: Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
Study: NCT01361828

Intervention type: PROCEDURE
Intervention: Electrophysiology
Description: Visual Evoked Potential and Elctroretinogram
Study: NCT02740959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Polysaccharides 500 mg
Description: PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Polysaccharides 250 mg
Description: PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
Study: NCT03199950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol 2dd1mg (08.00am - 10.00pm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral 2dd (08.00am - 10.00pm)